Pharmaceuticals Malaysia

Malaysia Radiopharmaceuticals Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Malaysia Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $14.7 Mn Placeholder estimate
Estimate 2025 $16.2 Mn 0.2% of the global market
Projected 2034 $39.5 Mn 143.6% Adds $23.3 Mn over 9 forecast years
CAGR 2025–2034 10.4% Faster than 62% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Malaysia is 0.18% of the global market.
  • In APAC, the largest is China at $813.1 Mn.
  • Fastest growing: India at 12.8% a year.
  • Malaysia ranks 7th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$23.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Radiopharmaceuticals Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $14.7 Mn — —
2025 (base) $16.2 Mn +$1.5 Mn —
2026 (forecast) $17.9 Mn +$1.7 Mn +10.4%
2027 (forecast) $19.8 Mn +$1.9 Mn +21.9%
2028 (forecast) $21.8 Mn +$2.1 Mn +34.6%
2029 (forecast) $24.1 Mn +$2.3 Mn +48.6%
2030 (forecast) $26.6 Mn +$2.5 Mn +64%
2031 (forecast) $29.3 Mn +$2.8 Mn +81.1%
2032 (forecast) $32.4 Mn +$3.1 Mn +99.9%
2033 (forecast) $35.8 Mn +$3.4 Mn +120.7%
2034 (forecast) $39.5 Mn +$3.7 Mn +143.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $9.08 Bn
  2. North America $4.23 Bn
  3. US $3.20 Bn
  4. APAC $1.89 Bn
  5. Europe $1.61 Bn
  6. Canada $810.3 Mn
  7. China $813.1 Mn
  8. Japan $623.3 Mn
  9. Middle East $380.3 Mn
  10. Latin America $363.4 Mn
  11. Germany $319.4 Mn
  12. France $271.0 Mn
  13. Brazil $259.9 Mn
  14. UK $242.1 Mn
  15. Italy $217.7 Mn
  16. Ecuador $206.3 Mn
  17. Spain $197.1 Mn
  18. India $167.4 Mn
  19. Africa $159.7 Mn
  20. Mexico $153.7 Mn
  21. Saudi Arabia $134.9 Mn
  22. Australia $111.2 Mn
  23. Russia $87.0 Mn
  24. New Zealand $86.7 Mn
  25. South Africa $65.3 Mn
  26. UAE $39.7 Mn
  27. Egypt $29.7 Mn
  28. Philippines $19.8 Mn
  29. Malaysia (this report) $16.2 Mn
  30. Hong Kong $14.3 Mn
  31. Singapore $10.9 Mn
  32. Thailand $9.8 Mn
  33. Kenya $6.7 Mn

Report snapshot

Malaysia Radiopharmaceuticals Market Analysis at a glance
Market size, 2025$16.2 Mn placeholder estimate
Forecast, 2034$39.5 Mn placeholder estimate
Growth (CAGR), 2025–203410.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, isotope and end user (see all)
Key playersNovartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and 1 more (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia Radiopharmaceuticals Market Analysis Executive Summary

Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.

Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).

Bar chart: Malaysia Radiopharmaceuticals market size, 2024–2034, placeholder estimates. $14.7 Mn in 2024, $16.2 Mn in 2025 and $39.5 Mn in 2034, 10.4% CAGR.
Malaysia Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia Radiopharmaceuticals Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.

Competitive Landscape for Radiopharmaceuticals Market in Malaysia

The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Malaysia

Radiopharmaceuticals in Malaysia: rules and payment

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.

Latest research 2,809 papers since 2021 (worldwide)

  1. Evaluation and an Exploratory Human Study of 99mTc-Labeled PSMA-Targeting Agents with Reduced Renal Uptake via Proline Incorporation. Journal of medicinal chemistry, 2026
  2. Synthesis and Preclinical Evaluation of Novel (203)Pb-PSMA Radioligands as Leads for the Development of (203/212)Pb-PSMA Theranostics. Molecular imaging and biology, 2026
  3. Radiopharmaceuticals in Molecular Neuroimaging: Radiotracers in Development. Neuroimaging clinics of North America, 2026
  4. Radiopharmaceuticals in Molecular Neuroimaging: Food and Drug Administration-Approved Radiotracers. Neuroimaging clinics of North America, 2026
  5. Nitroimidazole containing cyclicpeptide [(68)Ga]Ga-ZJUIQB-G002 as a new FAP-targeting radionuclide tracer. European journal of medicinal chemistry, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Radiopharmaceuticals in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Radiopharmaceuticals market in Malaysia?
Placeholder estimate: about $16.2 Mn in 2025, rising to about $39.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Malaysia growing?
Placeholder estimate: about 10.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Who regulates Radiopharmaceuticals in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Radiopharmaceuticals in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on oncology

See the topic